國家衛生研究院 NHRI:Item 3990099045/14135

NHRI > National Institute of Infectious Diseases and Vaccinology > Hsin-Wei Chen > Periodical Articles > Item 3990099045/14135

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14135

Title:	A novel chimeric dengue vaccine candidate composed of consensus envelope protein domain III fused to C-terminal-modified NS1 protein
Authors:	Huang, HJ;Yang, M;Chen, HW;Wang, S;Chang, CP;Ho, TS;Kao, YS;Tien, SM;Lin, HH;Chang, PC;Lai, YC;Hsiao, YP;Liu, YL;Chao, CH;Anderson, R;Yeh, TM;Lin, YS;Wan, SW
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	There is an urgent need for a safe and effective vaccine against dengue virus (DENV) which infects about 390 million humans per year. In the present study we combined modifications of two DENV proteins, the nonstructural protein 1 (NS1) and the envelope (E) protein, to produce a DENV vaccine candidate with enhanced features. One of these modified proteins was a C-terminal-deleted fragment of NS1 called ΔC NS1 which we have shown previously to be protective without the potentially harmful effects of cross-reactive epitopes common to surface antigens on platelets and endothelial cells. The other modified protein was an envelope protein domain III (cEDIII) containing a consensus amino acid sequence among the four serotypes of DENV, which induces neutralizing antibody against all four DENV serotypes. The cEDIII and ΔC NS1 were expressed as a fusion protein cEDIII-ΔC NS1 and its protective effects against DENV were evaluated in a mouse model. C3H/HeN mice were immunized three times with cEDIII-ΔC NS1 fusion protein mixed with alum as adjuvant. Sera collected from cEDIII-ΔC NS1-immunized mice neutralized four serotypes of DENV and also caused complement-mediated cytolysis of HMEC-1 cells infected with each of the four different DENV serotypes. Mice immunized with cEDIII-ΔC NS1 and challenged with DENV showed reduced serum virus titer, soluble NS1 and bleeding time, compared with mice infected with DENV alone. The results reveal that antibodies induced by cEDIII-ΔC NS1 not only show anti-viral efficacy by in vitro assays but also provide protective effects against DENV infection in a mouse model. The cEDIII-ΔC NS1 thus represents a novel, effective DENV vaccine candidate.
Date:	2022-04
Relation:	Vaccine. 2022 Apr;40(15):2299-2310.
Link to:	http://dx.doi.org/10.1016/j.vaccine.2022.02.070
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0264-410X&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000820771800010
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85126312776
Appears in Collections:	[Hsin-Wei Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85126312776.pdf		3574Kb	Adobe PDF	162	View/Open

Loading...